CBG, CBN, and CBC: The Minor Cannabinoids Explained

Why Minor Cannabinoids Matter

• Cannabis produces over 100 distinct cannabinoids beyond THC and CBD
• CBG, CBN, and CBC have growing research interest for their therapeutic potential
• EU-GMP certified products document minor cannabinoid content on COAs
• The entourage effect suggests minor cannabinoids contribute to overall therapeutic character

Minor cannabinoids are an emerging frontier in cannabis pharmacology — and one reason why whole-plant EU-GMP products may outperform isolates.

CBG, CBN, and CBC Profiles

• CBG (cannabigerol): the mother cannabinoid — anti-inflammatory, neuroprotective, antibacterial properties studied
• CBN (cannabinol): produced by THC degradation — purported sedative effects, may contribute to sleep-promoting profiles
• CBC (cannabichromene): interacts with TRP channels involved in pain — anti-inflammatory, analgesic, potential neurogenesis effects
• All three are non-psychoactive and contribute to the full-spectrum character of whole-plant preparations

Minor cannabinoid documentation in EU-GMP COAs allows clinicians to consider the full phytochemical profile when selecting products for specific patients.